Vivos Therapeutics, Inc. (VVOS)
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $17.4M
- Net income
- -$21.2M
- Total assets
- $25.2M
- Market cap
- $12.0M
- Gross margin
- 60.4%
- Operating margin
- -114.1%
- Net margin
- -121.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $17.4M
- Cost of revenue
- $6.9M
- Gross profit
- $10.5M
- Operating expenses
- $30.4M
- Operating income
- -$19.9M
- Net income
- -$21.2M
- EPS (basic)
- $-2.07
- EPS (diluted)
- $-2.07
Balance sheet
- Total assets
- $25.2M
- Current assets
- $4.4M
- Total liabilities
- $26.7M
- Current liabilities
- $18.1M
- Shareholders’ equity
- -$1.6M
Cash flow
- Operating cash flow
- -$15.3M
- Investing cash flow
- -$7.5M
- Financing cash flow
- $18.6M
- Net cash flow
- -$4.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $12.0M
- EPS (diluted)
- $-2.07
- Shares outstanding
- 30.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 11, 2020
Vivos Therapeutics, Inc. (VVOS) Stock Price
- Reported a net loss of $21.2M in FY2025.
- Revenue grew 3% from FY2021 to FY2025.
- Gross margin of 60.4%, net margin -121.7%.
- Trading 94% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vivos Therapeutics, Inc..
Write a review
News about Vivos Therapeutics, Inc.
News & sentiment via Polygon.io
Vivos Therapeutics, Inc.: frequently asked questions
Is Vivos Therapeutics, Inc. an American company?
Vivos Therapeutics, Inc. is a US-based company headquartered in Littleton, Colorado, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Vivos Therapeutics, Inc. headquartered?
Vivos Therapeutics, Inc. is headquartered in Littleton, Colorado, United States.
Is Vivos Therapeutics, Inc. publicly traded?
Yes — Vivos Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol VVOS on the NASDAQ.
What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc. is an American Medical Devices company in the Health & Beauty sector.
